Correspondence 0001213900-26-041468 from 20/20 Biolabs, Inc. (AIDX)
20/20 Biolabs, Inc.
Date: April 8, 2026 · CIK: 0001139685 · Accession: 0001213900-26-041468
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294903
Letter
Re: 20/20 Biolabs, Inc.
20/20 Biolabs, Inc.
15810 Gaither Road, Suite 235
Gaithersburg, MD 20877
April 8, 2026
U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC. 20549 Attn: Robert Augustin
Registration Statement on Form S-1 (File No. 333-294903)
Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended, 20/20 Biolabs, Inc. hereby respectfully requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-1 (the "Registration Statement") and declare the Registration Statement effective at 5:00 p.m. (Eastern Time) on Friday, April 10, 2026, or as soon thereafter as practicable.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Louis A. Bevilacqua of Bevilacqua PLLC at (202) 869-0888, ext. 100 .
Respectfully,
20/20 Biolabs, Inc.
Show Raw Text
CORRESP 1 filename1.htm 20/20 Biolabs, Inc. 15810 Gaither Road, Suite 235 Gaithersburg, MD 20877 April 8, 2026 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC. 20549 Attn: Robert Augustin Re: 20/20 Biolabs, Inc. Registration Statement on Form S-1 (File No. 333-294903) Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended, 20/20 Biolabs, Inc. hereby respectfully requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-1 (the "Registration Statement") and declare the Registration Statement effective at 5:00 p.m. (Eastern Time) on Friday, April 10, 2026, or as soon thereafter as practicable. It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Louis A. Bevilacqua of Bevilacqua PLLC at (202) 869-0888, ext. 100 . Respectfully, 20/20 Biolabs, Inc. By: /s/ Jonathan Cohen Jonathan Cohen Chief Executive Officer cc: Louis A. Bevilacqua, Esq.